Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The MRC Anatomical Neuropharmacology Unit at the University of Oxford (MRC ANU) closed on the 31 March after 30 years of world leading research on the complex networks of the brain. From 1 April, the ANU becomes  the Medical Research Council Brain Network Dynamics Unit at the University of Oxford (MRC BNDU). 

Our goal is to understand and exploit the interactions between nerve cells that are critical for brain functions, with a special focus on the brain circuits underlying movement and memory...we aim to develop and deliver novel therapies that specifically target the disturbed circuit interactions arising in disease.
- Professor Peter Brown

The new unit, led by director Professor Peter Brown, will build on the previous unit's success, using animal models and patients to understand brain circuitry in some of the most prevalent and debilitating brain disorders such as Parkinson’s disease, memory disorders and Alzheimer’s disease.

The MRC BNDU will be uniquely multidisciplinary and integrate research programmes covering clinical, experimental and computational neuroscience in both the Department of Pharmacology and the Nuffield Department of Clinical Neurosciences.

Read more...

Similar stories

Two neurologists awarded MRC Senior Clinical Fellowships

Clinical Neurology Research

Two of our Associate Professors, Sarosh Irani and George Tofaris, have been awarded MRC Senior Clinical Fellowships.

Developing diagnostics for COVID-19

Clinical Neurology Coronavirus Research

Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.

COVID-19 and Guillain-Barré syndrome

Clinical Neurology Coronavirus Research

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

Clinical Neurology Coronavirus Research

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.

Emerging Leaders Prize celebrates outstanding pain researchers

Award Clinical Neurology

2020’s Emerging Leaders Prize awards £200,000 to outstanding scientists from the University of Oxford, University College London and King’s College London, who are all working in the field of pain research.

MRC New Investigator Award for John Dawes

Clinical Neurology Research

Neuropathic pain arises from disease or damage of the nervous system. It is a major clinical problem affecting 5-10% of the adult population, despite the use of current therapies.